14605-22-2 Tauroursodeoxycholic acid dihydrate AKSci J52324
 
 
Loading Please Wait...
  J52324    AKSci Bulk Reagent
Tauroursodeoxycholic acid dihydrate, 95%
 
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid N-(2-sulfoethyl)amide
TUDCA
IDENTITY
CAS Number:14605-22-2
MDL Number:MFCD09750398
MF:C26H45NO6S·2H2O
MW:499.71 (anhydrous)
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form (at 20°C):Solid
Melting Point:139-153°C
Optical Rotation:+42-+48° (c=1, EtOH)
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

REVIEW
 Tauroursodeoxycholic acid (TUDCA) is an ambiphilic bile acid and is the conjugate form of ursodeoxycholic acid and taurine. Ongoing research finds TUDCA has apoptotic effects, helping with cardiac function, Huntington's disease, Parkinson's Disease, and stroke. Recently, TUDCA has been found to have protective effects in the eye, especially for retinal degenerative disorders. Bax, a molecule that is translocated to the mitochondria to release cytochrome C, initiates the cellular pathway of apoptosis. TUDCA prevents Bax from being transported to the mitochondria. This protects the mitochondria from perturbation and the activation of caspases; therefore TUDCA acts as a chemical chaperone. Recent studies continue to show ocular protective effects via protecting retinal rods against apoptosis, choroidal neovascularization and synaptic connectivity.

REFERENCES
[1]Bonaldi, Antonio; Molinari, Egidio Preparation of taurine-conjugated bile acids Eur. Pat. Appl. (1994), EP 582891 A2 19940216.
[2] Huang, Ling; Zhang, Heping; Qin, Heping; Shen, Huibing; Huang, Wenjun; Liu, Yisong Method for preparation of tauroursodeoxycholic acid hydrate Faming Zhuanli Shenqing (2012), CN 102558268 A 20120711.
[3] Boatright, Jeffrey H.; Nickerson, John M.; Moring, Anisha G.; Pardue, Machelle T. Bile acids in treatment of ocular diseases. Journal of Ocular Biology, Diseases, and Informatics 2009, 2 (3): 149-159.
[4] Boatright, Jeffrey H, Nickerson, John M, Moring, Anisha G, Pardue, Machelle T. Bile acids in treatment of ocular diseas. J Ocul Biol Dis Infor 2009, 2 (3): 149-159.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

RELATED PRODUCTS
M937Tauroursodeoxycholic acid dihydrate
4482ABSodium tauroursodeoxycholate

Current as of April 24, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > Bile Acids


PubChem
  @PubMed